key: cord-0684672-a2lsj5av
authors: Li, Zhengtu; Li, Yinhu; Li, Linghua; Mo, Xiaoneng; Li, Shaoqiang; Xie, Mingzhou; Zhan, Yangqing; Lin, Ye; Li, Zhun; Xie, Min; Chen, Zhaoming; Zhu, Airu; Ying, Ruosu; Yu, Le; Zhao, Jincun; Li, Shuai Cheng; Cai, Weiping; Ye, Feng
title: Alteration of the respiratory microbiome in COVID-19 patients with different severities
date: 2021-11-17
journal: J Genet Genomics
DOI: 10.1016/j.jgg.2021.11.002
sha: 9fa2a92b2fdda9e9769e1ee8ac6131f566d56bf0
doc_id: 684672
cord_uid: a2lsj5av

nan

COVID-19 cases and 4,654,898 deaths as of 14 March 2021, although 300,002,228 vaccines have been administered globally. COVID-19 patients have different clinical phenotypes and can be divided into asymptomatic, normal, mild, severe, and critical patients. However, the factors that lead to severe/critical cases remain controversial, and microecological dysfunction is one of the potential causes (Saleh et al., 2020) . Previous studies have reported that the gut microbiome affects the severity of COVID-19 (Zuo et al., 2020; Lv et al., 2021) , but the correlations between the respiratory microbiome (RM) and COVID-19 severity have seldom been detected. Since the RM is closely related to the occurrence of COVID-19 (Wypych et al., 2019) , we propose to explore the RM characteristics in COVID-19 patients with different severities and elucidate the RM changes along with the clinical treatment.

In this study, we recruited 39 COVID-19 patients from The First Affiliated Hospital of Guangzhou Medical University and Guangzhou Eighth People's Hospital, including 12 asymptomatic (Group 1), 15 normal/mild (Group 2), and 12 severe/critical (Group 3) patients (Supplementary Methods; Table S1 ). After clinical examinations in all COVID-19 patients (Table S1) , we compared the clinical indices between the three groups and discovered a deteriorated clinical situation in the older patients (Fig. S1 ). Compared with asymptomatic patients, COVID-19 patients with normal/mild symptoms had significantly increased blood pressure and decreased leukocytes (adjusted P < 0.05; Fig. S1 ), which was clinical evidence of viral infection. Among the severe/critical COVID-19 patients, we observed disordered clinical indices, such as decreased heart beats and lymphocytes and increased blood pH and body temperature (adjusted P < 0.05; Fig. S1 ). Generally, the findings are in accordance with those of previous studies, and the worsened vital signals in older patients suggest a high risk of developing severe/critical cases Zhou et al., 2020) .

To investigate potential bacterial infections, we collected sputum samples from the COVID-19 patients and detected their RMs with the Oxford Nanopore Technology sequencing platform (Supplementary Methods). A total of 4,692,525 clean reads, which were longer than 100 bp, were J o u r n a l P r e -p r o o f generated with an average of 120,316.1 ± 148,799.4 per sample. After taxonomical annotation, we discovered that the reads were assigned to 1,157 genera in all samples. Based on the clinical indices and the Bray-Curtis distance matrix obtained from RM compositions, we performed the permutational analysis of variance (PERMANOVA; Table S2 ) and discovered that disease severity (R 2 = 0.083, P < 0.01) contributed significantly to the RM differences (Fig. 1A) . Additionally, principal coordinate analysis (PCoA) revealed the overlap of Group 1 and Group 2 and the separation of Group 3 (Fig. 1B) .

These results suggested that COVID-19 patients with different severities had different RM characteristics, and the severe/critical patients exhibited more distinct RM features as compared with the asymptomatic and normal/mild patients. However, we did not observe significantly different bacterial diversity among the three groups, which might have been caused by the insufficient sample size (Fig. 1C ). To detect the common RM alterations in patients, we selected the top 10 abundant genera from Group 1, Group 2, and Group 3, respectively, and found distinct RM compositions between the groups. The severe/critical patients exhibited significantly decreased abundances of Neisseria, Rothia, and Prevotella (adjusted P < 0.05; Fig. 1D ), which are generally abundant in healthy people (Schenck et al., 2016; Man et al., 2017) , partially consistent with previous discoveries.

Moreover, the distinct RM characteristics in Group 3 were confirmed when we performed sample clustering based on the top 10 abundant genera (Fig. S2 ). To further confirm the altered species in severe/critical patients, we selected the top 10 abundant species from the three groups and discovered the significantly decreased Neisseria mucosa, Neisseria subflava, Rothia mucilaginosa, Prevotella intermedia, and Prevotella jejuni (adjusted P < 0.05; Fig. S3 ). Since individual RM differences were detected among patients in Group 3, we analyzed their RM and discovered individually enriched pathogens, such as abnormally abundant Parvimonas (40.93% in patient 8752), Flavobacterium (12.91% in patient 7336), Staphylococcus (9.35% in patient 4706), and Gardnerella (46.76% in patient 8015, Table S3 ). We deduced that the asymptomatic/normal/mild COVID-19 patients possessed RM with characteristics similar to those of healthy people. Conversely, the severe/critical patients contained individually distinct RM features, which differentially infecting pathogens may cause (Man et al., 2017; Wu and Segal, 2018) .

To further detect the longitudinal alteration of the RM in association with COVID-19 during clinical treatment, we collected sputum from the severe/critical patients the day after enrolment (T1), J o u r n a l P r e -p r o o f two weeks after treatment (T2), and one day before discharge from the hospital (T3). Notably, PCoA revealed a high coincidence of samples from the T2 and T3 groups after clinical treatment, distinct from the T1 group, suggesting significant impacts of treatment on the RM (Fig. 1E ). Since we have applied antibiotics to the severe/critical patients, we speculated that the results were caused by antibiotic application (Table S1 ). In addition, we further performed beta-diversity to detect the RM differences among the T1, T2 and T3 groups, and confirmed the significantly altered RM in T2 and T3 patients after clinical treatment (Fig. S4) . However, the RM diversity in the patients did not change statistically during clinical treatment, although decreased Shannon diversity was observed (Fig. 1F ).

During treatment, we discovered continually increased Rothia and Prevotella, suggesting the recovery of RM balance in the patients (Figs. 1G and S5). We also found decreased pathogens, such as Gardnerella (from 46.76% to in patient 8015) and Parvimonas (from 40.93% to in patient 8752), hinting at eliminating pathogens and reducing bacterial infection risks (Table S4) . However, Lactobacillus, which is recognized as a probiotic, also decreased. Therefore, we speculated that the phenomena were caused by the indiscriminate elimination of bacteria by antibiotics (Schwartz et al., 2020) , and we should remain cautious during antibiotic application.

Applying Spearman correlation analysis to the RM and clinical indices, we found positive correlations between body temperature and Aggregatibacter (R = 0.433, adjusted P < 0.05) and

Haemophilus (R = 0.408, adjusted P < 0.05), which implied the potential relationships between the increased pathogens and the aggravated inflammations in patients ( Fig. 1H ; Table S5 ). Meanwhile, lymphocytes positively correlated to Vibrio (R = 0.376, P < 0.05) and Selenomonas (R = 0.426, adjusted P < 0.05). In contrast, systolic blood pressure is negatively associated with the abundance of Escherichia in the respiratory tract (R = ˗0.525, adjusted P < 0.05). To discriminate COVID-19 patients with different severities, we further constructed a Random Forest model using the RM compositions. In the model, the area under the curve (AUC) value reached 0.714 with 3-fold validation (Fig. 1I) . Facilitated by respiratory biomarkers for distinguishing patients with different severities (Fig. S6) , the COVID-19-risk model could predict the clinical severity of the enrolled COVID-19 patients.

From previous reports, we have learned that the gut microbiome involves the severity of COVID-19 through the host's immune system (van der Lelie and Taghavi, 2020; Yeoh et al., 2021) , and the characteristics of the RM in association with COVID-19 with different severities remain unexplored. This study explored the RM in COVID-19 patients with different severities, but there were several shortcomings. First, we lacked RM controls from healthy people, enabling us to detect the magnitude of RM alterations in COVID-19 patients. Second, limited by the small sample size, the accuracy of the COVID-19 risk model needs to be improved with samples from other countries. Last but not least, we should perform the gut metagenomic and immunologic examinations in the patients, helping us gain a deeper insight into the roles of microbiome on clinical severities.

In conclusion, our study revealed differences in RM characteristics in COVID-19 patients with different severities, emphasized bacterial coinfection in severe/critical patients, and established a COVID-19-risk model for predicting the coinfection or clinical severity of COVID-19 patients.

The clinical information for the patients and the taxonomic information of the respiratory microbiome can be accessed in the Supplementary data. All other information is available from the authors upon reasonable rquest.

The authors declare that they have no conflicts of interest. 

Group1 Group2 Group3 Group1 Group2 Group3 Group1 Group2 Group3 Group1 Group2Group3

Strategies and Advances in Combating COVID-19 in China

The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes

The microbiota of the respiratory tract: gatekeeper to respiratory health

Mitochondria and microbiota dysfunction in COVID-19 pathogenesis

Composition and immunological significance of the upper respiratory tract microbiota

Understanding the impact of antibiotic perturbation on the human microbiome

COVID-19 and the Gut Microbiome: More than a Gut Feeling

The Lung Microbiome and Its Role in Pneumonia

The influence of the microbiome on respiratory health

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study